Innoviva, Inc. — Director's Dealing 2013

Aug 1, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: THERAVANCE INC (THRX)
CIK: 0001080014
Period of Report: 2013-07-30

Reporting Person: Mammen Mathai (SVP, Research & Early Clin Dev)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-07-30	Common Stock	S	7000	$36.51	Disposed	211705	Direct

Footnotes

F1: DISPOSITIONS MADE PURSUANT TO A PLAN INTENDED TO COMPLY WITH RULE 10b5-1(c).

F2: This transaction was executed in multiple trades at prices ranging from $36.16 to $37.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.